Beam Therapeutics Inc. - Common Stock (BEAM) stock analysis

BEAM · Beam Therapeutics Inc. - Common Stock

Latest recorded price: USD 20.94

Sector and industry: Healthcare · Biotechnology

Fiscal 2025 figures: revenue growth 31.9%, free cash flow margin -257.7%, ROIC -89.5%. The model flags 1 risk signal for this company (1 high severity).

Similar companies in Healthcare